Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Publication year range
3.
Tunis Med ; 96(10-11): 665-671, 2018.
Article in English | MEDLINE | ID: mdl-30746659

ABSTRACT

INTRODUCTION: Breast cancer is often diagnosed at a late stage in Tunisia with long delay in time to consultation and to diagnosis. The aim of the study was to identify explanatory factors to delayed diagnosis. METHODS: A case control analytical was performed from January 2013 to December 2014 in the department of Medical Oncology in FarhatHachedUniveristy Hospital.Patients with the diagnosis of ductal breast carcinoma were included in the study.Characteristics of a first group of 200 women with locally advanced or metastatic breast cancer (G1)were compared to a second group of 200 patients with early stage (G2). RESULTS: Median delay in consultation and mean tumor size were significantly more important in group G1 (p<0,001).A low level of schooling, a rural origin, poor socio-economic conditions and no encouragement by the patient relatives do not allow an early diagnosis.Misinterpretation of clinical breast signs was the only explanatory factor related to the system. In multivariate study, a low level of schooling(adjusted OR=2.72; CI 95% [1,65-4,49]), no encouragement by the patient's relatives(adjusted OR=7.86; CI 95% [4,24-14,57])and more than three dependants(adjusted OR=2.49; CI 95% [1,58-3,93]) were the independent factors that could explain the delay in diagnosis. CONCLUSION: Our study confirm the inverse relationship between socio-economic and scholar level and disease stage. Health education campaigns particularly among women with a low schooling level and of rural origin could reduce time for consultation. Promoting continuing medical education could avoid diagnostic errors.


Subject(s)
Breast Neoplasms/diagnosis , Breast Neoplasms/epidemiology , Carcinoma, Ductal, Breast/diagnosis , Carcinoma, Ductal, Breast/epidemiology , Delayed Diagnosis/statistics & numerical data , Adult , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Carcinoma, Ductal, Breast/pathology , Carcinoma, Ductal, Breast/therapy , Case-Control Studies , Delayed Diagnosis/adverse effects , Delayed Diagnosis/prevention & control , Female , Health Knowledge, Attitudes, Practice , Health Services Accessibility/statistics & numerical data , Humans , Middle Aged , Patient Acceptance of Health Care , Risk Factors , Socioeconomic Factors , Time Factors , Time-to-Treatment/statistics & numerical data , Tumor Burden , Tunisia/epidemiology
4.
Rev Pneumol Clin ; 69(3): 149-51, 2013 Jun.
Article in French | MEDLINE | ID: mdl-23582264

ABSTRACT

Intramedullary spinal cord metastases are extremely rare and affect 0.1 to 0.4% of all cancer patients. We report the case of intramedullary metastases in a 42-year-old patient, 12 months after the initial diagnosis of a lung adenocarcinoma. The patient was on third-line chemotherapy for a progressive disease with node and bone metastases. He complained of weakness and difficulty walking. The MRI permitted confirmation of the diagnosis. Corticotherapy was started and the patient underwent radiotherapy. A targeted therapy was indicated. The patient died three months after the initiation of this treatment. The aim of this paper is to report a new case of intramedullary spinal cord metastases from a pulmonary adenocarcinoma, focus on its rarity and diagnostic and therapeutic difficulties through a review of the literature.


Subject(s)
Adenocarcinoma/pathology , Lung Neoplasms/pathology , Spinal Cord Neoplasms/secondary , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/drug therapy , Adenocarcinoma of Lung , Adult , Antineoplastic Agents/therapeutic use , Disease Progression , Erlotinib Hydrochloride , Fatal Outcome , Humans , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/drug therapy , Male , Quinazolines/administration & dosage , Radiography , Spinal Cord Neoplasms/diagnostic imaging , Spinal Cord Neoplasms/drug therapy
5.
Cancer Radiother ; 16(7): 627-32, 2012 Oct.
Article in French | MEDLINE | ID: mdl-23084987

ABSTRACT

PURPOSE: To assess the epidemiological, clinical and therapeutic aspects of pediatric Hodgkin disease (HD) and to study prognosis factors. PATIENTS AND METHODS: We retrospectively reviewed the medical records of children (≤18 years) with HD treated between 1st January 1994 and 31st December 2004. Chemotherapy was undertaken in different departments of hematology and oncology in the North of the country and radiotherapy was centralized at the Salah-Azaïz National Cancer Institute. RESULTS: One hundred fourteen consecutively treated patients were collected. Median age was 12 years (4-18 years) and sex-ratio was 2.25. Peripheral lymphadenopathy was the predominant circumstance of HD detection (82.5%). The predominant histologic type was nodular sclerosing (56%). Treatment included chemotherapy and involved-field radiotherapy. With a mean follow-up of 23.5 months, relapse rate was 12.2%. Five-year overall survival (OS) and event-free survival (EFS) rates were 95% and 76%, respectively. Five-year OS was 98.2% and 90.8% for early and advanced stages respectively. In multivariate analysis, stage IV (P=0.029) and early response to initial treatment (P=0.003) retained statistical significance for EFS whereas the only prognostic factor for OS was stage IV (P=0.002). The long-term side effects were rare. No secondary tumor was noted. CONCLUSION: Combined-modality therapy using chemotherapy and involved-field radiotherapy was effective and well-tolerated in early stage pediatric HD. Stage IV patients should be referred to specialized units for intensive treatment. The short median follow-up in our study cannot allow considering long-term effects.


Subject(s)
Hodgkin Disease/epidemiology , Adolescent , Anemia, Aplastic/etiology , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bleomycin/administration & dosage , Bleomycin/adverse effects , Cardiomyopathy, Dilated/chemically induced , Chemoradiotherapy , Child , Child, Preschool , Cisplatin/administration & dosage , Cisplatin/adverse effects , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Etoposide/administration & dosage , Etoposide/adverse effects , Female , Hodgkin Disease/therapy , Humans , Ifosfamide/administration & dosage , Ifosfamide/adverse effects , Male , Mechlorethamine/administration & dosage , Mechlorethamine/adverse effects , Photons/therapeutic use , Prednisone/administration & dosage , Prednisone/adverse effects , Procarbazine/administration & dosage , Procarbazine/adverse effects , Radiotherapy Dosage , Remission Induction , Retrospective Studies , Risk Factors , Treatment Outcome , Tunisia/epidemiology , Vincristine/administration & dosage , Vincristine/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...